Stereotactic conformal radiotherapy of hepatic metastases: clinical analysis of 8 cases

Abstract

Key Words: liver neoplasms/radiotherapy; liver neoplasm s/secondary; stereotactic conformal radiotherapy

INTRODUCTION

It is always a routine to resect lesions of the body by surgery. Scientists have tried to obtain the same results without surgery, but failed. In recent years, with the development of multi-subject and high technology, lesions can be localized precisely with stereotactic technique. And with the help of computer and medical imaging technique, stereotactic conformal radiotherapy (SCR) has become a "no pain, no blood" surgery. At the same time, SCR is recognized globally, its therapeutic range has transferred from intracranial lesions to the lesions of extracranial sites of the body, and is expected to become an important method in conventional surgery. Therefore, it is called "surgery of the 21 century"[1]. From May 1997 to April 1998, we treated 8 cases of hepatic metastases with SCR and the results are reported below.

MATERIALS AND METHODS

Materials

Eight patients (4 men and 4 women, 1-5 metastases/person) who received stereotactic high-dose radiation therapy for hepatic metastases (21 lesions) using an accelerator were included. Treatments were given from May 1997 to April 1998. The age ranged from 67 to 46 years (mean 55.4). Three cases had one lesion, 5 had more than one lesions (one case had 5 metastases). The maximal clinical target volume (CTV) was 232 cm³, and the minimal CTV 0.6 cm³. The majority of the patients had previously received treatment for various types of primary tumors. At the time of treatment most patients had one known lesion increased in size as assessed by repeated CT scanning. Biopsies for histopathological examinations were obtained from some patients during open surgery. The majority of the irradiated lesions were considered so typical for metastases.

Methods

Stereotactic conformal radiotherapy The stereotactic body-frame was used in treatment. For targets affected by the diaphragmatic motions due to breathing, a device was developed to minimize the motions to 1 cm or less[2]. The reproducible position of the patient in the frame was obtained by the vacuum pillow and two markers, chest and tibia marker respectively. These markers are set to predefined stereotactic coordinates, at which the markers should correspond to the tattoo-points on the skin over sternum and tibia to ensure a high reproducibility in the cranial-caudal direction.

Therapeutic technique Primarily, a positioning and drawing plan was worked out. A stereotactic system (including stereotactic setting and localization) was used for stereotactic radiotherapy (SRT) to improve the accuracy of localization and setting-up. A consecutive CT scan of 2 mm slice thickness was outlined manually on the computer screen in every horizontal CT-slice for patients with hepatic metastases. Target point and width of the collimator was calculated with specially designed computor programs. Beam′s eye view technique with digitally reconstructed radiographs from the transverse CT scans was adopted to design the 3-D treatment plan. The 3-D treatment planning is a conformal technique, using 6-8 non-coplanar stationary beams. On multi-leaf collimator, the shape of be am eye view was similar with the target in all directions. Patients were all treated with a liner accelerator (VARIAN Clinic 600C). The photon energies used were 6 Mev.

Dose distribution The dose planning was made on a 3-D system (Virtuos 2.8.0). Apart from dose distributions, the clinical target volume (CTV), planning target volume (PTV), and organs at risk volumes were also calculated. Several factors were taken into consideration when the dose/fraction was determined. These included size of the CTV, dose distribution with dose-volume histograms and radiation sensitivity of the surrounding normal tissues. In this series, the CTV of tumors ranged from 0.6 cm³ to 232 cm³ (mean 36.4 cm³), the prescribed dose (PD) was 4-6.5 Gy (mean 5.13 Gy). Treatments were given in 2-8 fractions. The total dose was 10-45 Gy/2-8 fractions.

RESULTS

None of the patients died during SRT. Their condition was evaluated by Karnofsky Performance Standard (KPS), 20-90 before treatment (mean 58.75) and 30-100 after treatment. Very few, if any, complications could be ascribed to the SRT. Three (37.5%) patients developed slight fever (< 37.8 °C). WBC count and hepatic function had no distinct changes. During a follow-up period of 2-9 months, complete response (CR) was found in two cases (Figure 1, Figure 2), partial response (PR) in three cases, no change (NC) in two cases and progressed (PD) in one case. After SCR, 87.5% of tumors were controlled (62.5% of the tumors decreased in size or disappeared). Three patients died during the follow-up period, one died of bone metastases 303 months, one died of MSOF 1.5 months and one died of hepatic failure 2.3 months after treatment (Table 1).

Table 1 Clinical data of hepatic metastases with stereotactic conformal radiotherapy.

	Patient No.
	1	2	3	4	5	6	7	8
Sex (M/F)	M	M	F	F	F	M	F	M
Age (years)	59	46	49	54	67	61	49	58
Primary tumor	Colon	Lung	Breast	Breast	Preventriculus	Stomach	Breast	Cholecyst
Number of irradiated tumor	1	3	1	4	2	5	4	1
Volume of clinical	34.5	1.9, 1.5	14.8	5.1, 0.6	18.4	232, 134.1	30.7, 11.6	120.3
target (cm3)		2.1		0.9, 0.9	16.7	75.2, 7.7, 23.7	3.3, 1.5
Prescribed dose (Gy)	5.00	4.50	5.00	5.00	5.00	4.00	6.00	6.50
Number of fractions	3	8	8	5	2	7	7	7
KPS before treatment	80	40	90	90	20	40	40	70
KPS after treatment	80	50	100	100	30	50	70	90
Size of tumor after irradiation	NC	PD	CR	CR	NC	PR	PR	PR
Time period of follow-up	8	4	6	6	2	3	3	2
Time period after irradiation (months)	Unknown	3.3	6	6	1.5	2.3	3	2

Figure 1 Preoperative CT image of patient with hepatic metastases of breast tumor.

Figure 2 Three months postoperative CT image of the same patient.

DISCUSSION

Most of all patients who receive SCR are advanced patients with tumor who underwent no surgery and conventional radiotherapy. Their prognosis is not well[3]. So SCR is a new method for late case of tumor.

Formation of SCR

In 1951, the term stereotactic radiosurgery was introduced by Leksell[4] who was a neurosurgeon in Karolinska Academy. In 1968, the first - knife of the world was developed successfully. It was an epochmaking event to neurosurgery and radiotherapy technique. Since the beginning of 1980, with the improvement of stereotactic system and collimator, stereotactic radiosurgery (X-knife)[5] has been performed to intracranial lesions with linear accelerator based radiosurgery, and soon the treatment extended from intracranial to extracranial tumors. For large and/or irregular lesions, linear accelerator, with circle and multi-leaf collimator was employed. The treatment can be achieved by a combination o f several non-coplanar rotational irradiations, each directed at the same point, thus representing a convergent beam irradiation technique. The 3-D treatment system demonstrates clinical superiority and flexibility to treatment planning.

Facilities and theory of SCR

Stereotactic radiotherapy is a system of 3-D treatment planning and radiotherapy-include hardware and software. X-knife software reconstructs radiograph from image data of CT, MRI and DSA. The 3-D treatment planning was designed by soft ware could be made standard or complex design based on these data from either single or multi-convergent. X-knife software can calculate radiation dose quickly and precisely. Dose-calculate formula is shown by dose-volume histograms (DVHs) on the screening display. Radiation dosage can be calculated by computer. Its important character is to deliver a highly focused radiation distribution to the target volume and to reduce the dose to surrounding normal tissues as much as possible[6].

Development of SCR

Since SCR technique came into being, it has been used to treat intracranial lesions, primarily the AVM and intracranial tumors. In recent years, with the development of stereotactic technique for treatment of intracranial tumors, X-knife technique began to be applied to treat tumors of mediastinum, liver and retroperitoneal metastases in Karolinska Hospital in Sweden in 1993. Lax et al[7] created a method to treat abdominal malignant tumors with high-dose stereotactic radiotherapy.

Evaluation of SCR

In stereotactic radiotherapy, stereotactic technique (localization and setting- up) is used to improve localization accuracy and setting-up accuracy. The difference between SRT and SRS is, the conception of the former is fractional radiotherapy, the latter is single fraction. When the size of the tumor is large, either from radiobiology and radiophysiology or from clinic, SRT must be adopted instead of SRS[8]. Patients treated with SRT all obtained good therapeutic effects. The development of SCR technique will enrich the conventional surgery means. In tumor treatment, SCR will exert an indispensable effect. With the accumulation of clinical experience, SRT will play an important role in treatment of malignancies.